Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Dingcheng Gao
Immune Reprogramming via PD-1 Inhibition Enhances Early-Stage Lung Cancer Survival
JCI insight
Medicine
Related publications
Social Factors, Treatment, and Survival in Early-Stage Non-Small Cell Lung Cancer.
American Journal of Public Health
Environmental
Public Health
Occupational Health
Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?
Cancer
Cancer Research
Oncology
Nuclear EGFR Protein Expression Predicts Poor Survival in Early Stage Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care
Surgery
Oncology
SBRT Effective for Inoperable Early-Stage Lung Cancer
Cancer Discovery
Oncology
Correction: Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-Cyfra 21-1 Autoantibody Immune Complex for Detection of Early Stage Lung Cancer
Chemical Communications
Surfaces
Alloys
Materials Chemistry
Coatings
Metals
Optical
Magnetic Materials
Films
Catalysis
Chemistry
Electronic
Composites
Ceramics
P3.16-42 Early Stage Non-Small Cell Lung Cancer Survival in a Chilean Private Teaching Hospital
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment
Journal of Cancer
Oncology